DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
- 1
- 2
Osteoarthritic Pain – As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? | Decision Base | US/EU5 | 2015
As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition…
- 1
- 2